Robert Huebner | Principal Consultant
Latham BioPharm Group

Dr. Huebner has over 30 years of experience in biologics development with a large focus on vaccines while working in large pharma companies, government agencies, and contract research organizations. At LBG, Dr. Huebner supports both commercial and U.S. Government-funded programs as a subject matter expert on biopharmaceutical advanced development, analytical testing, strategic planning, and program management. He also leads the vaccine practice and is part of the team that helps clients win and secure non-dilutive U.S. Government funding.
Prior to joining LBG, Dr. Huebner worked at the Biomedical Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), where he held several positions, including Deputy Director and Acting Director of the Influenza Division and Chief of Universal Influenza Vaccine Development. While serving as Acting Director, he was responsible for more than 50 programs valued in excess of $5 billion. His tenure in this position was highlighted by the licensure of three new types of influenza vaccines and the approval of a new near patient diagnostic platform for influenza and RSV. Prior to his roles at BARDA, Dr. Huebner worked at MRIGlobal, bringing in projects from U.S. Government and industrial clients to work on vaccines, detection methods, and destruction methods for bacterial and viral pathogens. He began his career as a bench scientist and group leader at Sanofi Pasteur, working on applied research to develop new and improved vaccines against Lyme disease, influenza, Dengue, Japanese Encephalitis, malaria, and pneumococcal disease.
Dr. Huebner received a Ph.D. in Molecular Biology and Microbiology from Tufts University and a B.S. in Biology from Carnegie Mellon University.